Bulletin
Investor Alert

Bio-Techne Corp.

NAS: TECH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Bio-Techne Corp.

After Hours

 --Quotes are delayed by 20 min

Aug 14, 2020, 5:22 p.m.

TECH
/zigman2/quotes/203973516/composite

$

261.03

Change

0.00 0.00%

Volume

Volume 2,596

Quotes are delayed by 20 min

/zigman2/quotes/203973516/composite

Previous close

$ 266.29

$ 261.03

Change

-5.26 -1.98%

Day low

Day high

$258.73

$265.74

Open

52 week low

52 week high

$155.17

$286.68

Open

Company Description

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies s...

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Valuation

P/E Current

44.85

P/E Ratio (without extraordinary items)

45.37

Price to Sales Ratio

14.09

Efficiency

Total Asset Turnover

0.37

Liquidity

Current Ratio

4.88

Quick Ratio

3.92

Cash Ratio

2.54

Profitability

Gross Margin

73.65

Operating Margin

21.31

Pretax Margin

37.43

Net Margin

31.04

Return on Assets

11.53

Return on Equity

18.01

Return on Total Capital

9.03

Capital Structure

Total Debt to Total Assets

21.38

Officers and Executives

Name Age Officer Since Title
Mr. Charles R. Kummeth 58 2013 President, Chief Executive Officer & Director
Mr. James T. Hippel 48 2014 CFO & Principal Accounting Officer
Dr. Robert Monroe - 2018 Chief Medical Officer
Mr. Kim Kelderman - 2018 President-Diagnostics & Genomics
Ms. Brenda Swierenga Furlow 61 2014 Secretary, Senior Vice President & General Counsel

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/09/2020 Charles R. Kummeth
Chief Executive Officer; Director 		12,287   Derivative/Non-derivative trans. at $265.76 per share. 3,265,393
08/09/2020 James T. Hippel
Chief Financial Officer 		2,184   Derivative/Non-derivative trans. at $265.76 per share. 580,419
08/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		849   Derivative/Non-derivative trans. at $265.76 per share. 225,630
08/09/2020 Norman David Eansor
President-Protein Sciences 		856   Derivative/Non-derivative trans. at $265.76 per share. 227,490
08/09/2020 Charles R. Kummeth
Chief Executive Officer; Director 		21,291   Derivative/Non-derivative trans. at $0 per share. 0
08/09/2020 James T. Hippel
Chief Financial Officer 		4,438   Derivative/Non-derivative trans. at $0 per share. 0
08/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		1,724   Derivative/Non-derivative trans. at $0 per share. 0
08/09/2020 Norman David Eansor
President-Protein Sciences 		2,174   Derivative/Non-derivative trans. at $0 per share. 0
08/05/2020 Charles R. Kummeth
Chief Executive Officer; Director 		8,586   Award at $0 per share. 0
08/03/2020 Julie L. Bushman
Director 		89   Award at $0 per share. 0
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		74   Disposition at $278.84 per share. 20,634
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		2,746   Disposition at $278.06 per share. 763,552
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		1,954   Disposition at $277.28 per share. 541,805
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		400   Disposition at $276.02 per share. 110,408
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		918   Disposition at $274.8 per share. 252,266
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		2,042   Disposition at $273.33 per share. 558,139
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		505   Disposition at $272.48 per share. 137,602
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		440   Disposition at $270.97 per share. 119,226
07/09/2020 Brenda Swierenga Furlow
SVP - General Counsel 		9,079   Derivative/Non-derivative trans. at $108.49 per share. 984,980
07/07/2020 James T. Hippel
Chief Financial Officer 		500   Disposition at $272.26 per share. 136,130
07/07/2020 James T. Hippel
Chief Financial Officer 		1,663   Disposition at $271.4 per share. 451,338
07/07/2020 James T. Hippel
Chief Financial Officer 		414   Disposition at $270.56 per share. 112,011
07/07/2020 James T. Hippel
Chief Financial Officer 		2,577   Derivative/Non-derivative trans. at $108.49 per share. 279,578
07/06/2020 James T. Hippel
Chief Financial Officer 		1,269   Disposition at $274.52 per share. 348,365
07/06/2020 James T. Hippel
Chief Financial Officer 		1,934   Disposition at $273.71 per share. 529,355
07/06/2020 James T. Hippel
Chief Financial Officer 		4,947   Disposition at $272.34 per share. 1,347,265
07/06/2020 James T. Hippel
Chief Financial Officer 		3,781   Disposition at $271.53 per share. 1,026,654
07/06/2020 James T. Hippel
Chief Financial Officer 		9,571   Disposition at $270.45 per share. 2,588,476
07/06/2020 James T. Hippel
Chief Financial Officer 		21,502   Derivative/Non-derivative trans. at $108.49 per share. 2,332,751
05/29/2020 Harold J. Wiens
Director 		3,985   Disposition at $260 per share. 1,036,100
05/29/2020 Norman David Eansor
President-Protein Sciences 		709   Disposition at $264.01 per share. 187,183
05/29/2020 Norman David Eansor
President-Protein Sciences 		2,100   Disposition at $262.68 per share. 551,628
05/29/2020 Norman David Eansor
President-Protein Sciences 		3,400   Disposition at $261.74 per share. 889,916
05/29/2020 Norman David Eansor
President-Protein Sciences 		1,700   Disposition at $260.83 per share. 443,411
05/29/2020 Harold J. Wiens
Director 		3,985   Derivative/Non-derivative trans. at $101.19 per share. 403,242
05/29/2020 Norman David Eansor
President-Protein Sciences 		7,909   Derivative/Non-derivative trans. at $108.49 per share. 858,047
05/28/2020 Brenda Swierenga Furlow
SVP - General Counsel 		3,800   Disposition at $260.38 per share. 989,444
05/28/2020 Brenda Swierenga Furlow
SVP - General Counsel 		2,195   Disposition at $259.72 per share. 570,085
05/28/2020 Norman David Eansor
President-Protein Sciences 		3,448   Disposition at $260.19 per share. 897,135
05/28/2020 Brenda Swierenga Furlow
SVP - General Counsel 		1,600   Derivative/Non-derivative trans. at $94.35 per share. 150,960
05/28/2020 Brenda Swierenga Furlow
SVP - General Counsel 		5,995   Derivative/Non-derivative trans. at $108.49 per share. 650,397
05/28/2020 Norman David Eansor
President-Protein Sciences 		3,448   Derivative/Non-derivative trans. at $108.49 per share. 374,073
05/26/2020 Charles R. Kummeth
Chief Executive Officer; Director 		13,018   Derivative/Non-derivative trans. at $266.4 per share. 3,467,995
05/26/2020 Charles R. Kummeth
Chief Executive Officer; Director 		21,159   Derivative/Non-derivative trans. at $86.25 per share. 1,824,963
05/22/2020 Harold J. Wiens
Director 		378   Gift at $0 per share. 0
05/22/2020 Norman David Eansor
President-Protein Sciences 		4,924   Disposition at $268.41 per share. 1,321,650
05/22/2020 Norman David Eansor
President-Protein Sciences 		7,676   Disposition at $267.62 per share. 2,054,251
05/22/2020 Norman David Eansor
President-Protein Sciences 		8,637   Derivative/Non-derivative trans. at $108.49 per share. 937,028
05/22/2020 Norman David Eansor
President-Protein Sciences 		3,963   Derivative/Non-derivative trans. at $94.35 per share. 373,909
/news/latest/company/us/tech

MarketWatch News on TECH

  2. Bio-Techne downgraded to hold from buy at Stifel Nicolaus

    6:49 a.m. May 27, 2020

    - Tomi Kilgore

  3. Bio-Techne started at buy with $290 stock price target at Benchmark

    6:25 a.m. May 14, 2020

    - Tomi Kilgore

  4. The Investment Allure of American Water Works

    10:30 p.m. Jan. 10, 2020

    - Barron's Online

  5. How to profit from the ‘best of both worlds’ in stock investing

    10:20 a.m. Sept. 23, 2019

    - Philip van Doorn

  6. The Best Mutual Funds You’ve Never Heard Of

    5:28 p.m. July 12, 2019

    - Barron's Online

  8. Five Ways to Play a Growing Health Sector

    1:40 a.m. Jan. 19, 2019

    - Barron's Online

  9. Bio-Techne stock value estimate raised to $180 from $148 at Janney

    2:01 p.m. Aug. 9, 2018

    - Tomi Kilgore

  10. These two trends will continue to power small-cap stocks

    7:50 a.m. July 19, 2018

    - Philip van Doorn

  11. 3 Growth Stocks for the Long Haul

    1:08 p.m. March 7, 2018

    - Barron's Online

  13. What Happened In Pharma Last Quarter?

    9:19 a.m. Aug. 18, 2017

    - Barrons Blogs

  14. Bio-Techne downgraded to neutral from buy at Janney

    7:56 a.m. March 27, 2017

    - Tomi Kilgore

  15. Bio-Techne started at buy with $115 stock price target at Deutsche Bank

    9:45 a.m. Jan. 18, 2017

    - Tomi Kilgore

  17. Tech Data expects deal to add to adjusted EPS in the first year after closing

    7:02 a.m. Sept. 19, 2016

    - Tomi Kilgore

  18. Tech Data to pay $2.4 bln in cash and 2.785 mln shares for Avnet's technology solutions business

    7:02 a.m. Sept. 19, 2016

    - Tomi Kilgore

  19. Tech Data to buy Avnet's technology solutions business in a deal valued at $2.6 bln

    7:01 a.m. Sept. 19, 2016

    - Tomi Kilgore

  20. Biotech Bull Is Starting to Show Cracks, Say Charts

    10:15 a.m. Aug. 11, 2015

    - Barron's Online

  21. Loading more headlines...
/news/nonmarketwatch/company/us/tech

Other News on TECH

  2. Bio-Techne develops new SARS-CoV-1/2 Spike RBD antibody

    8:07 a.m. Aug. 11, 2020

    - Seeking Alpha

  3. Bio-Techne debuts new SARS-CoV-1/2 Spike RBD antibody

    8:07 a.m. Aug. 11, 2020

    - Seeking Alpha

  5. Notable earnings before Tuesday's open

    12:47 p.m. Aug. 3, 2020

    - Seeking Alpha

  10. Tracking Ron Baron's BAMCO Portfolio - Q1 2020 Update

    7:03 p.m. June 14, 2020

    - Seeking Alpha

  14. 10-Q: BIO-TECHNE CORP

    6:37 a.m. May 11, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  18. Notable earnings before Thursday's open

    5:30 p.m. April 29, 2020

    - Seeking Alpha

  19. Tracking Ron Baron's BAMCO Portfolio - Q4 2019 Update

    10:30 a.m. March 23, 2020

    - Seeking Alpha

  20. Stocks To Watch: Time For Coronavirus Offense Or Defense?

    9:26 a.m. Feb. 29, 2020

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Bio-Techne Corp.

614 McKinley Place NE

Minneapolis, Minnesota 55413-2610

Phone

1 6123792956

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

06/2021

View SEC Filings

Revenue

$738.69M

Net Income

$229.30M

Employees

-

Annual Report for TECH

/news/pressrelease/company/us/tech

Press Releases on TECH

  8. Bio-Techne Declares Dividend

    6:30 a.m. Aug. 4, 2020

    - PR Newswire - PRF

  9. Bio-Techne Releases Fourth Quarter Fiscal 2020 Results

    6:30 a.m. Aug. 4, 2020

    - PR Newswire - PRF

  21. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.